confid recoveri build near-term mileston critic reiter ow
invest summari reiter ow rate pt
first earn call new ceo bryan hanson lower expect
speed recoveri provid level transpar next step potenti
challeng investor appreci focu step
need restor full suppli management plan work regain
trust sale organ launch new product drive revenu
acceler provid full-year guidanc choos
wait earn call could visibl come
materi event transit certain product contract manufactur given
valuat view risk/reward attract current level think
could signific upsid continu recov
solid result report solid top-lin organ growth
sequenti improv factset consensu growth
driven stronger ortho market apac stock recoveri
procedur hurrican impact accord management ep
line consensu
guidanc suggest sequenti step-down sale ep y/i growth
provid revenu growth guidanc ex-fx adjust
one less sell day midpt growth expect slow
sequenti due softer ortho market apac stock delay
elect procedur uk also provid ep guidanc
 wait better visibl give full-year guidanc
provid full-year guidanc choos wait earn call
management want get past key materi event transit non-autom
process contract manufactur re-inspect north campu
facil provid visibl restor full suppli
expect gradual revenu recoveri new ceo
commit fix suppli constraint although said suppli
constraint may resolv end revenu acceler may occur
quickli management said one key object restor trust sale
organ take time expect limit launch new
product energ salesforc exit expect full launch
month later drive revenu acceler expect revenu
growth gradual improv throughout broader recoveri
continu
 valuat price target base price-to-earnings multipl
disclosur section may found page
reinvest tax-reform benefit acceler revenu growth plan reinvest
tax benefit current reform approxim compani also expect incur
compens headwind mileston pay manag expect gross
margin compar expect gm lower
end rang due headwind north campu remedi spend
expect gm higher end rang compani anniversari remedi
spend lower revenu growth rate forecast ex-fx
reflect gradual path recoveri outlin expect adjust dilut ep
y/i versu prior estim
sourc compani document factset cantor fitzgerald estim
exhibit comparison cantor estim
compani document factset cantor fitzgerald estim
inc million except per extrem dilut inc million except per share current priorcurr priorp growth growth gener adminstr incom expens tax provis dilut share januari
zbh oper issu leadership uncertainti warrant discount peer
 said think zbh valuat could quickli rebound move toward
histor averag post coupl strong quarter rebuild investor confid
price target base price-to-earnings multipl ep estim
manufactur issu suppli constraint could persist resolut manufactur issu
north campu delay sever occas expect move past
issu full resolut could delay
fda could take addit action said on-track remedi plan
address observ fda return facil retest although
expect fda return near term fda could potenti issu warn letter take
action could neg affect zbh oper
may abl recaptur share lost meaning amount hip knee share
last two year histor share shift given year ten basi
point may abl recaptur share quickli lost
million except per share data
cost good sold
sell gener adminstr
interest expens incom
incom incom tax
sell gener adminstr
amort intang
sell gener adminstr
compani document cantor fitzgerald research
zimmer biomet headquart warsaw indiana found becam public compani august spun
bristol-my squibb june zimmer acquir biomet deal creat current zimmer biomet pure-
play orthoped compani knee revenu hip revenu make total compani sport medicin
extrem trauma spine dental sale
